Fig. 1 · Structure

Documents & Downloads

Clofibrate

Cat. No. A10229 CAS 637-07-0
Clofibrate increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Clofibrate bound recombinant full-length human and mouse PPARα in an intrinsic-fluorescence quenching assay, with reported Kd values of 58 ± 6 and 39 ± 6 nM, respectively (mean ± SE, n ≥ 3). These assay-specific affinities should be distinguished from cellular activation concentrations. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PPARα EC50 50 μM
PPARγ EC50 500 μM

In Vitro Studies

In MCF-7 and A2780 cancer cells, clofibrate at 100–500 μM reduced hypoxia-induced HRE reporter activity and HIF-1α protein after 4 h pretreatment followed by 16 h at 1% oxygen. This cell-based response does not establish antitumor efficacy in animals or humans. [2]

Intrinsic-fluorescence binding to full-length PPARα

Biochemical assay · Purified full-length, untagged recombinant human and mouse PPARα [1]

Clofibrate quenched intrinsic receptor fluorescence; rosiglitazone showed no determinable binding. Reported Kd values are biochemical affinity estimates, not cellular EC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Clofibrate binding to human PPARαKd 58 ± 6 nM (mean ± SE; n ≥ 3)[1]
Clofibrate binding to mouse PPARαKd 39 ± 6 nM (mean ± SE; n ≥ 3)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing clofibrate concentrations; receptor concentration 0.1 μM
Method
Intrinsic aromatic amino acid fluorescence quenching at 24°C; excitation 280 nm; background and inner-filter correction
Reported limits
Incubation duration and clofibrate vehicle not specified in the selected quenching method. No independent chemical analysis of clofibrate reported in the read material.
Methods and source locations

Compound reported in the paper: Clofibrate; Compound label in the paper: Clofibrate as named by the authors; no Adooq lot validation

Reported experimental clofibrate only; conditions and responses are model specific.

Methods: Chemicals, recombinant protein purification, intrinsic-fluorescence quenching; Results; Tables 1–2; Figures 1, 3K/L, 4K/L

Clofibrate binding to human PPARα: Intrinsic receptor fluorescence quenching — Table 1 clofibrate row and footnote; Figure 3K and caption

Clofibrate binding to mouse PPARα: Intrinsic receptor fluorescence quenching — Table 2 clofibrate row and footnote; Figure 4K and caption

Clofibrate attenuates hypoxic HIF signaling in cancer cells

Cell-based study · Human MCF-7 breast cancer and A2780 ovarian carcinoma cells [2]

Clofibrate reduced hypoxia-induced HRE reporter activity and HIF-1α protein across the tested concentrations. The adopted phenotype does not establish therapeutic efficacy or a uniquely PPARα-dependent mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hypoxia-induced HRE reporter activity in MCF-7 and A2780 cellsConcentration-response direction Reduced with increasing clofibrate exposure; reporter data mean ± S.E., n = 3[2]
Hypoxia-induced HIF-1α proteinImmunoblot direction Reduced; representative images from three individual experiments[2]

Literature-Reported Treatment Conditions

Treatment concentration
100, 300 and 500 μM; 0 μM hypoxia and normoxia controls
Exposure duration
4 h pretreatment, followed by 16 h at 1% O2
Method
HRE-luciferase reporter assay and HIF-1α immunoblotting with β-actin control
Reported limits
Clofibrate vehicle not identified in the read methods. No exact percentage inhibition is extracted from bar heights.
Methods and source locations

Compound reported in the paper: Clofibrate; Compound label in the paper: Clofibrate as named by the authors; no Adooq lot validation

Reported experimental clofibrate only; conditions and responses are model specific.

Materials; cell culture; luciferase and Western blot methods; statistics; Figure 2A–D and caption

Hypoxia-induced HRE reporter activity in MCF-7 and A2780 cells: Luciferase normalized to protein; percentages relative to untreated normoxic cells — Figure 2A,C and caption; luciferase assay methods

Hypoxia-induced HIF-1α protein: HIF-1α immunoblot with β-actin control — Figure 2B,D and caption

In Vivo Studies

In lactating sows fed 2 g clofibrate/kg diet for a 21-day lactation, day-20 plasma TAG and NEFA were lower than in controls. Hepatic target-gene responses were selective: CPT1A increased, whereas ACOX1 did not differ significantly. Milk fat and litter gains were not significantly changed; milk protein increased. These findings are specific to the tested feeding and lactation conditions. [3]

Metabolic and lactation outcomes after dietary clofibrate

Animal study · Twenty second-parity Large White and German Landrace sows; randomized after parturition, 10 per group; litters standardized to eight piglets [3]

Dietary clofibrate lowered plasma TAG and NEFA and selectively increased PPARα target transcripts. Milk fat and litter gains did not differ significantly; milk protein increased. These are outcomes of one feeding experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Day-20 plasma triacylglycerolConcentration Control 0.37 ± 0.13 vs clofibrate 0.23 ± 0.09 mmol/L; P = 0.029; mean ± SD, n = 10/group[3]
Day-20 plasma nonesterified fatty acidsConcentration Control 152 ± 66 vs clofibrate 64 ± 18 μmol/L; P = 0.002; mean ± SD, n = 10/group[3]
Day-20 hepatic CPT1A mRNARelative expression Control 1.00 ± 0.75 vs clofibrate 3.86 ± 1.77; P = 0.003; mean ± SD, n = 10/group[3]
Day-20 hepatic ACOX1 mRNARelative expression Control 1.00 ± 0.61 vs clofibrate 1.16 ± 0.65; P = 0.577; mean ± SD, n = 10/group[3]
Day-20 milk fatContent Control 6.81 ± 0.49 vs clofibrate 6.92 ± 1.15%; P = 0.797; mean ± SD, n = 10/group[3]
Day-20 milk proteinContent Control 5.19 ± 0.39 vs clofibrate 5.66 ± 0.33%; P = 0.012; mean ± SD, n = 10/group[3]
Litter weight gain, day 1–21Weight gain Control 45.0 ± 6.88 vs clofibrate 46.1 ± 5.25 kg; P = 0.704; mean ± SD, n = 10/group[3]

Conditions shared by the study groups

Route
Oral, mixed into basal diet
Frequency
Daily feeding
Treatment course
21-day lactation; day-20 sampling
Vehicle
Basal diet
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dietary clofibrate
2 g/kg diet
Ten sows receiving the same basal diet without clofibrateLower plasma TAG and NEFA, selective target-gene response, unchanged milk fat and litter gains by significance testing; increased milk protein[3]
Dietary clofibrate
Model: Lactating second-parity sows; 10 animals
Reported limits: No measured systemic drug exposure; no pharmacokinetic attribution to parent ester versus metabolites
Methods and source locations

Compound reported in the paper: Clofibrate; Compound label in the paper: Clofibrate as named by the authors; no Adooq lot validation

Reported experimental clofibrate only; conditions and responses are model specific.

Methods: Animals and diets, sample collection, plasma lipid assays, qPCR, milk analysis, statistics; Tables 3–6 and corresponding Results

Day-20 plasma triacylglycerol: Enzymatic assay; Student’s t test — Table 4 TAG row and footnote; Concentration of TAG and NEFA in plasma; Statistical analysis

Day-20 plasma nonesterified fatty acids: Enzymatic assay; Student’s t test — Table 4 NEFA row and footnote

Day-20 hepatic CPT1A mRNA: qPCR with GeNorm normalization — Table 3 liver CPT1A row and footnote; RNA isolation and qPCR

Day-20 hepatic ACOX1 mRNA: qPCR with GeNorm normalization — Table 3 liver ACOX1 row and footnote

Day-20 milk fat: Official VDLUFA milk analysis methods — Table 5 Fat row and footnote

Day-20 milk protein: Official VDLUFA milk analysis methods — Table 5 Protein row and footnote

Litter weight gain, day 1–21: Litter weighing; litters standardized to eight piglets — Table 6 Day 1–day 21 gain row and footnote

Dietary clofibrate · Animals and diets; sample collection; Tables 3–6

Specifications

Manufacturer Adooq Bioscience
CAS Number 637-07-0
Formula C12H15ClO3
Molecular Weight 242.7
SMILES
CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 7 mg/mL (28.84 mM)
Water Insoluble
Ethanol 5 mg/mL (20.6 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Dhawal P Oswal, Madhumitha Balanarasimha, Jeannette K Loyer, et al. Divergence between human and murine peroxisome proliferator-activated receptor alpha ligand specificities Journal of Lipid Research (2013). PMID: 23797899 DOI: 10.1194/jlr.M035436 Source material
  2. [2] Jundong Zhou, Shuyu Zhang, Jing Xue, et al. Activation of Peroxisome Proliferator-activated Receptor α (PPARα) Suppresses Hypoxia-inducible Factor-1α (HIF-1α) Signaling in Cancer Cells The Journal of Biological Chemistry (2012). PMID: 22932900 DOI: 10.1074/jbc.M112.367367 Source material
  3. [3] Denise K Gessner, Birthe Gröne, Susann Rosenbaum, et al. Treatment of lactating sows with clofibrate as a synthetic agonist of PPARα does not influence milk fat content and gains of litters BMC Veterinary Research (2015). PMID: 25888880 DOI: 10.1186/s12917-015-0368-y Source material

Added to your cart

View Cart Checkout
Loading...